Clinical trials
Advanced Tumors clinical trials
Below are recruiting advanced tumors clinical trials, each written for real people, not researchers. We’re tracking 1,349 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03486873RecruitingPhase 3
Study extension for people on pembrolizumab, testing long-term safety
This trial follows people with advanced tumors who are already on pembrolizumab (or similar treatment) to check long-term safety and effectiveness. It may help your care team by monitoring benefits and side effects over a longer period.
Tucson, ArizonaAges 18 years+ - NCT06413212Recruiting
Personalized drug test for advanced cancer with fluid buildup
This trial uses a special test on your cancer cells to find which chemotherapy might work best for you. The aim is to treat advanced cancer that has caused fluid buildup in the chest or abdomen.
Wuhan, HubeiAges 18 years+ - NCT07265921RecruitingPhase 1
Study of SIM0609 for advanced solid tumors
This trial tests an investigational new drug, SIM0609, for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see early signs that it might help slow or shrink tumors.
BeijingAges 18 years+ - NCT06413953RecruitingPhase 1
Testing TQB3107 for advanced solid tumors
This trial is testing a new oral medication called TQB3107 for people with advanced solid tumors (cancer that has spread or cannot be removed). The study aims to see if the drug is safe and how well it works.
Guangzhou, GuangdongAges 18–75 - NCT06401356RecruitingPhase 3
Long-term study for people already taking pelabresib
This is a follow-up study for people who are already taking the drug pelabresib in another trial and are doing well on it. It allows you to continue receiving pelabresib and monitors your health over a longer period.
Los Angeles, CaliforniaAges 18 years+ - NCT06684327RecruitingPhase 2
Study of three chemotherapy drugs for rare advanced cancers
This trial tests a combination of three chemotherapy drugs (albumin-paclitaxel, ifosfamide, and cisplatin) for people with certain rare cancers that have spread to other parts of the body (stage IV). It looks at how well the treatment works and if it is safe.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07348211RecruitingPhase 1
Study of SIM0610 for advanced solid tumors
This trial tests a new drug called SIM0610 for people with advanced solid tumors that have stopped responding to standard treatments. The study aims to see if the drug is safe and effective.
Chongqing, Chongqing MunicipalityAges 18 years+ - NCT07432295RecruitingPhase 2
Givastomig plus nivolumab and chemo for advanced stomach cancer
This trial tests a new drug, givastomig, combined with standard immunotherapy (nivolumab) and chemotherapy for people with advanced stomach, gastroesophageal junction, or esophageal cancer. It is for people whose tumors have certain markers (CLDN18.2 and PD-L1) and who have not had treatment for advanced disease.
Goodyear, ArizonaAges 18 years+ - NCT05036226RecruitingPhase 1/Phase 2
COAST therapy for advanced prostate or other solid tumors
This early-phase trial tests the COAST therapy approach in people with advanced solid tumor cancers or advanced prostate cancer that has continued to grow despite standard treatments. The study aims to see how well the treatment works and whether it is safe enough to continue studying.
Charleston, South CarolinaAges 18 years+ - NCT06687070RecruitingPhase 1
APG-2449 alone or with PLD for advanced cancers
This trial tests a new drug, APG-2449, either alone or with another chemotherapy called PLD (pegylated liposomal doxorubicin). It is for people with advanced solid tumors, including ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if the drug can shrink tumors and how safe it is.
Guangzhou, GuangdongAges 18 years+ - NCT06410131RecruitingPhase 1
Safety study of FTL008.16 for advanced solid tumors
This trial tests an investigational drug called FTL008.16 for people with advanced solid tumors that may carry a protein called 5T4. The main goal is to see if the drug is safe and tolerable.
Beijing, Beijing MunicipalityAges 18–75 - NCT05315700RecruitingPhase 1/Phase 2
ORIC-114 for advanced lung or breast cancers with EGFR or HER2 changes
This early-phase study tests ORIC-114 to treat advanced solid tumors that have certain EGFR or HER2 genetic changes, often found in lung and breast cancers. It may help by targeting those specific cancer mutations, especially when standard treatments no longer work or aren’t tolerated.
Duarte, CaliforniaAges 18 years+ - NCT05491083RecruitingPhase 1/Phase 2
Pembrolizumab plus ADG106 for advanced triple-negative breast cancer
This early-phase study tests pembrolizumab (an immune therapy) combined with ADG106 in people with advanced solid tumors, and specifically triple-negative breast cancer. It looks at whether the treatment can shrink tumors and improve outcomes for cancers that are progressing despite prior therapy.
SingaporeAges 21–99 - NCT06813079RecruitingPhase 2
Using tumor models to find your best treatment
This trial uses a personalized approach where a sample of your tumor is grown in the lab to test which drugs might work best for you. It is for people with advanced pancreatic cancer that cannot be surgically removed.
Toronto, OntarioAges 18 years+ - NCT06866964RecruitingPhase 2
Aspirin to prevent blood clots in advanced germ cell cancer chemotherapy
This trial tests if daily aspirin can prevent dangerous blood clots in people receiving chemotherapy for advanced testicular or germ cell cancer. It is for those at high risk of clots and aims to improve safety during treatment.
Charlotte, North CarolinaAges 18–70 - NCT06943755RecruitingPhase 2/Phase 3
Zanzalintinib vs Everolimus for Neuroendocrine Tumors
This trial compares a new targeted therapy (zanzalintinib) with an existing drug (everolimus) for people with advanced neuroendocrine tumors (NETs). It aims to see which treatment works better and may offer a new option for patients whose cancer has grown despite previous treatments.
Birmingham, AlabamaAges 18 years+ - NCT05679674Recruiting
Radiation plus at-home tumor device for locally advanced pancreatic cancer
This trial tests whether combining targeted radiation with an at-home “tumor treating fields” device can better control locally advanced pancreatic cancer. It may help by attacking cancer cells in more than one way after prior chemotherapy.
Miami, FloridaAges 18 years+ - NCT05262491RecruitingPhase 1
Early drug study for advanced GI or solid cancers that failed treatment
This Phase 1 trial tests BL-B01D1, a new cancer medicine, in people with advanced or metastatic gastrointestinal or other solid tumors that did not respond to standard treatment (or cannot use standard treatment). It also looks at whether a tumor marker called TROP2 may help predict who benefits.
Beijing, Beijing MunicipalityAges 18–75 - NCT06636435RecruitingPhase 1
Study of CBA-1205 for advanced cancers including liver, melanoma, and pediatric cancer
This trial tests a new drug called CBA-1205 for people with advanced solid tumors, liver cancer, melanoma, or certain childhood cancers that have not responded to standard treatments. The drug targets a protein called DLK1 found on some cancer cells.
Kashiwa, ChibaAges 2 years+ - NCT07029399RecruitingPhase 1
Study of NKT5097 for advanced solid tumors
This trial tests an experimental oral drug (NKT5097) for people with advanced solid tumors that have not responded to other treatments. It may also be an option for people with a specific type of breast cancer (HR+/HER2-). The goal is to see if the drug is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT03772561RecruitingPhase 1
Testing AZD5363, olaparib, and durvalumab for advanced solid cancers
This Phase 1 trial tests a combination of three medicines to shrink or control advanced solid tumors that are progressing or no standard options exist. It mainly focuses on safety and early signs of how well the treatment works.
Singapore, SingaporeAges 21–99 - NCT04353375RecruitingPhase 2/Phase 3
Study drug for FGFR2-mutated bile duct cancer
This trial tests HMPL-453 to treat advanced intrahepatic cholangiocarcinoma (bile duct cancer) that has an FGFR2 change. It may help shrink tumors or control the disease in people whose cancer has not responded well to prior treatment.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06983743RecruitingPhase 1
ERAS-0015 for Advanced Solid Tumors With RAS Mutations
This trial tests an experimental oral drug called ERAS-0015 for people with advanced solid tumors that have certain genetic changes (RAS mutations). It may be an option if you have no standard treatments left or cannot take them.
Santa Rosa, CaliforniaAges 18–99 - NCT07189195RecruitingPhase 1
TR-002 for advanced solid tumors and pancreatic cancer
This trial tests a new drug called TR-002 in people with advanced solid tumors (cancer that has spread) who have run out of standard treatment options. It includes a specific group for people with pancreatic cancer that is no longer responding to chemotherapy.
Sacramento, CaliforniaAges 18 years+
Hear when a new Advanced Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced tumors?
- Yes. Clin2 currently lists 1,349 recruiting advanced tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Advanced or Metastatic Solid Tumors
- Locally Advanced or Metastatic Solid Tumors
- Advanced Malignant Tumors
- Advanced/Metastatic Solid Tumors
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Patients With Advanced Solid Tumors
- Locally Advanced/Metastatic Solid Tumors
- Mesothelin-positive Advanced Malignant Solid Tumors
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.